| Bioactivity | Ladirubicin (PNU-159548) is a derivative of Daunorubicin (HY-13062A). Ladirubicin exhibits DNA intercalation and DNA alkylating properties, inhibits DNA replication and transcription, causes DNA damage, and thereby exhibits antitumor efficacy. Ladirubicin exhibits the potential to penetrate the blood-brain barrier (BBB) for its high lipophilicity. Ladirubicin exhibits toxicity through suppression of bone marrow activity[1]. |
| CAS | 171047-47-5 |
| Formula | C29H31NO11S |
| Molar Mass | 601.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Monneret C. Recent developments in the field of antitumour anthracyclines. Eur J Med Chem. 2001 Jun;36(6):483-93. |
Ladirubicin
CAS: 171047-47-5 F: C29H31NO11S W: 601.62
Ladirubicin (PNU-159548) is a derivative of Daunorubicin (HY-13062A). Ladirubicin exhibits DNA intercalation and DNA alk
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.